Stock 4114 SYNMOSA BIOPHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Synmosa Biopharma Corporation

Equities

4114

TW0004114004

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 18:00:00 2024-05-09 EDT 		5-day change 1st Jan Change
39.55 TWD +1.15% Intraday chart for Synmosa Biopharma Corporation +2.06% +2.33%
03-29 Synmosa Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
01-16 Synmosa Biopharma Corporation Announces Changes in Fifth Session of the Remuneration Committee CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 5,223 5,638 6,814 7,016 16,021 14,706
Enterprise Value (EV) 1 7,188 8,288 9,770 9,490 17,958 15,489
P/E ratio 13.6 x 116 x 10.4 x 23.1 x 19.9 x 24 x
Yield 0.73% - 1.19% 2.15% 1.14% 1.55%
Capitalization / Revenue 2.21 x 2.1 x 2.24 x 2.17 x 3.65 x 2.86 x
EV / Revenue 3.04 x 3.09 x 3.22 x 2.93 x 4.09 x 3.01 x
EV / EBITDA 87.4 x 58.7 x 22.3 x 19.9 x 23.6 x 16.7 x
EV / FCF -18.4 x -24.2 x -34.6 x 22.6 x 49.6 x 104 x
FCF Yield -5.45% -4.14% -2.89% 4.43% 2.02% 0.96%
Price to Book 1.63 x 1.61 x 1.51 x 1.49 x 2.98 x 2.2 x
Nbr of stocks (in thousands) 314,584 336,057 360,529 357,823 359,534 380,503
Reference price 2 16.60 16.78 18.90 19.61 44.56 38.65
Announcement Date 19-03-28 20-03-31 21-03-22 22-03-31 23-03-31 24-03-29
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,363 2,680 3,038 3,235 4,386 5,140
EBITDA 1 82.2 141.3 438 477.1 760.8 927.9
EBIT 1 -61.1 -106.7 149.5 186.7 460.7 616.8
Operating Margin -2.59% -3.98% 4.92% 5.77% 10.5% 12%
Earnings before Tax (EBT) 1 324.7 -144.6 497.6 153.9 725 601.6
Net income 1 430.9 47.09 638.1 303.9 799.1 594.8
Net margin 18.23% 1.76% 21% 9.39% 18.22% 11.57%
EPS 2 1.220 0.1450 1.816 0.8474 2.242 1.610
Free Cash Flow 1 -391.5 -342.8 -282.5 420.1 362.1 148.4
FCF margin -16.57% -12.79% -9.3% 12.99% 8.26% 2.89%
FCF Conversion (EBITDA) - - - 88.06% 47.6% 16%
FCF Conversion (Net income) - - - 138.27% 45.32% 24.96%
Dividend per Share 2 0.1212 - 0.2240 0.4212 0.5100 0.6000
Announcement Date 19-03-28 20-03-31 21-03-22 22-03-31 23-03-31 24-03-29
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3
Net sales 1 - 1,106 1,256 - 1,234
EBITDA - - - - -
EBIT 1 - 81.31 154.4 - 139.9
Operating Margin - 7.35% 12.29% - 11.33%
Earnings before Tax (EBT) - - - - -
Net income 401.3 - - 163.6 -
Net margin - - - - -
EPS 1.125 - - 0.5000 -
Dividend per Share - - - - -
Announcement Date 22-08-12 22-11-11 23-03-31 23-08-11 23-11-13
1TWD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 1,965 2,651 2,956 2,474 1,937 783
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 23.9 x 18.76 x 6.75 x 5.186 x 2.547 x 0.8434 x
Free Cash Flow 1 -392 -343 -282 420 362 148
ROE (net income / shareholders' equity) 6.95% -3.07% 8.82% 1.93% 9.71% 5.49%
ROA (Net income/ Total Assets) -0.51% -0.82% 0.98% 1.13% 2.68% 3.36%
Assets 1 -84,906 -5,746 65,247 26,940 29,860 17,692
Book Value Per Share 2 10.20 10.40 12.50 13.20 15.00 17.60
Cash Flow per Share 2 1.410 1.390 1.770 2.430 3.070 2.400
Capex 1 68.2 183 154 93.1 129 207
Capex / Sales 2.89% 6.84% 5.08% 2.88% 2.95% 4.03%
Announcement Date 19-03-28 20-03-31 21-03-22 22-03-31 23-03-31 24-03-29
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SYNMOSA BIOPHARMA CORPORATION Stock Synmosa Biopharma Corporation
+2.33% 465M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4114 Stock
  4. Financials Synmosa Biopharma Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW